MUMBAI, India, Feb. 6 -- Intellectual Property India has published a patent application (202541123565 A) filed by Saveetha Institute Of Medical And Technical Sciences, Chennai, Tamil Nadu, on Dec. 8, 2025, for 'efficacy of a novel combination gel containing adapalene 0.1%, azelaic acid 10%, glycerin 4% and squalance 2% compared to adapalene 0.1%, monotherapy in patients with mild to moderate acne vulgaris: a randomized comparative study.'
Inventor(s) include Vishnu Karthika. R; Rajesh Kumar. S; and Deepak Nallaswamy Veeraiyan.
The application for the patent was published on Feb. 6, under issue no. 06/2026.
According to the abstract released by the Intellectual Property India: "Efficacy of a Novel Combination Gel Containing Adapalene 0.1 %, Azelaic Acid I 0%, Glycerin 4%, and Squalane 2% Compared to Adapalene 0.1% Monotherapy in Patients with Mild to Moderate Acne Vulgaris: A Randomized Comparative Study The present invention relates to a novel fixed-dose topical gel formulation fofthe treatment of mild to moderate acne vulgaris. The composition comprises Adapalene 0.1 %, Azelaic Acid I 0%, Glycerin 4%, and Squalane 2% in a pharmaceutically acceptable gel base. Adapalene provides comedo lytic and anti-inflammatory activity, while Azelaic Acid exerts antimicrobial, keratolytic, and anti-tyrosinase effects, addressing both lesions and post-inflammatory hypcrpigmcntation. Glycerin and Squalanc improve hydration, barrier function, and tolerability, reducing irritation associated with retinoid therapy. The fommlation offers advantages over existing adapalene-benzoyl peroxide products by combining complementary therapeutic actions with enhanced skin comfort. Clinical evaluation in a randomized comparative study aims to demonstrate superior efficacy and tolerability of the novel combination gel compared to adapalene monotherapy, thereby providing a safe, effective, and patient-friendly treatment option for acne vulgaris."
Disclaimer: Curated by HT Syndication.
